通过表观遗传变化的结直肠癌的发病和生物标志物
Chang Kyo Oh1, Young-Seok Cho2
1Division of Gastroenterology, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
Intestinal research
|January 31, 2024
概括
大肠直肠癌 (CRC) 涉及遗传和表观遗传变化. 表观遗传改变正在成为CRC早期检测,预后和治疗反应的关键生物标志物.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 结肠直肠癌 (CRC) 是全球癌症死亡的主要原因.
- CRC的发展涉及到影响关键细胞过程的遗传和表观遗传变化的积累.
- 表观遗传变化,包括DNA甲基化和非编码RNA失调,是癌症的标志.
研究的目的:
- 审查CRC表观遗传变化的基本原则.
- 检查表观遗传修饰作为CRC生物标志物的作用.
- 讨论它们在早期检测,预后和预测治疗反应中的应用.
主要方法:
- 关于CRC表观遗传学的文献综述.
- 对生物标志物发现的基因组技术的分析.
- 对CRC中的表观遗传生物标志物进行当前研究的综合.
主要成果:
- 表观遗传改变是CRC瘤发生的组成部分.
- 基因组技术有助于识别表观遗传生物标记物.
- 这些生物标志物在CRC管理中显示出临床应用的前景.
结论:
- 表观遗传修饰对于结直肠癌的发展至关重要.
- 新兴的表观遗传生物标志物为改善CRC诊断和治疗提供了潜力.
- 需要进一步的研究才能将这些发现完全转化为临床实践.
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K


